Janssen And ViiV: Giving HIV/AIDS Patients Options Is Key
With EU submissions for once-monthly long-acting anti-HIV antivirals in hand, Janssen and ViiV appear to have set their sights on providing patients with more options.
With EU submissions for once-monthly long-acting anti-HIV antivirals in hand, Janssen and ViiV appear to have set their sights on providing patients with more options.